Day End Prices will be available on InvestorsLounge.com !


Pakistan Pharma: CY24: Improving profitability prospects - By JS Research

  • By: JS Global Capital Limited

  • - Published: Thursday, 27 March 2025
Pharmaceuticals.jpg
<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">We analyse CY24 performance of the listed pharmaceutical sector, using a sample size of nine companies. The year remained positive for the sector, mainly due to stable currency and raw material prices, coupled with the deregulation of non-essential drug pricing, which enabled companies to pass on cost impacts as needed to ensure the availability of key drugs.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">During CY24, our sample companies cumulatively posted a significant topline growth of 20% YoY, reaching Rs297bn, mainly driven by an increase in drug pricing, which supported 9ppts YoY higher gross margins to 35%. Likewise, the bottom line came in at Rs22bn, reflecting a 3x YoY growth.</span></l...

Similar Reports